Skip to main content

Table 5 OS and PFS (ITP group)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

 

Median OS (months)

Median PFS (months)

Protein Expression

Low

High

P-value

Low

High

P-value

 ERCC1

21.4

10.5

0.049

8.2

6

0.558

 COX2

17.7

10.5

0.363

7.9

6

0.895

 Tubulin B3

11.9

16.4

0.529

8.2

7.9

0.74

 CD4

11.9

25.5

0.397

6.6

10.1

0.113

 CD8

11.9

5.4

0.476

7.9

1.2

0.707

SNPs

        

 MDR1 C3435T

CC

TT

CT

P-value

CC

TT

CT

P-value

 

3.4

11.9

11.7

0.467

1.8

8.8

8.1

0.484

 MDR1 G2677 T

GG

TT

GT

 

GG

TT

GT

 
 

11.9

2.9

21.9

0.647

6.5

2.9

8.6

0.494

 ERCC1C8092A

AA

CC

CA

 

AA

CC

CA

 
 

25.2

11.9

11.9

0.664

10.2

7.9

6.5

0.702

 ERCC1 N118 N

CC

TT

CT

 

CC

TT

CT

 
 

11.6

21.6

5.6

0.401

8.2

10.1

3.6

0.003